DSpace About DSpace Software 日本語

01 奈良県立医科大学 >
012 大学院 >
0122 学位請求論文 >
01221 博士論文(医学) >
2018年度 >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10564/3557

Title: Childhood cancer incidence and survival in Japan and England: A population-based study (1993-2010).
Other Titles: がん登録データを用いた、小児がんの罹患率・死亡率の日英比較(1993-2010年)
Authors: Nakata, Kayo
Ito, Yuki
Magadi, Winnie
Bonaventure, Audrey
Stiller, Charles A.
Katanoda, Kota
Matsuda, Tomohiro
Miyashiro, Isao
Pritchard-Jones, Kathy
Rachet, Bernard
Keywords: cancer registry data
childhood cancer
childhood cancer incidence and survival
population-based study
Issue Date: Feb-2018
Publisher: John Wiley & Sons, Inc.
Citation: Cancer science Vol.109 No.2 p.422-434 (2018 Feb)
Abstract: The present study aimed to compare cancer incidence and trends in survival for children diagnosed in Japan and England, using population-based cancer registry data. The analysis was based on 5192 children with cancer (age 0-14 years) from 6 prefectural cancer registries in Japan and 21 295 children diagnosed in England during 1993-2010. Differences in incidence rates between the 2 countries were measured with Poisson regression models. Overall survival was estimated using the Kaplan-Meier method. Incidence rates for Hodgkin lymphoma, renal tumors and Ewing sarcomas in England were more than twice as high as those in Japan. Incidence of germ cell tumors, hepatic tumors, neuroblastoma and acute myeloid leukemia (AML) was higher in Japan than in England. Incidence of all cancers combined decreased in Japan throughout the period 1993 to 2010, which was mainly explained by a decrease in registration of neuroblastoma in infants. For many cancers, 5-year survival improved in both countries. The improvement in survival in chronic myeloid leukemia (CML) was particularly dramatic in both countries. However, 5-year survival remained less than 80% in 2005-2008 in both countries for AML, brain tumors, soft tissue sarcomas, malignant bone tumors and neuroblastoma (age 1-14 years). There were significant differences in incidence of several cancers between countries, suggesting variation in genetic susceptibility and possibly environmental factors. The decrease in incidence for all cancers combined in Japan was related to the cessation of the national screening program for neuroblastoma. The large improvement in survival in CML coincided with the introduction of effective therapy (imatinib).
Description: 博士(医学)・乙第1425号・平成31年3月15日
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
This is an open access article under the terms of the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
URI: http://hdl.handle.net/10564/3557
ISSN: 13479032
Academic Degrees and number: 24601B1425
Degree-granting date: 2019-03-15
Degree name: 博士(医学)
Degree-granting institutions: 奈良県立医科大学
Appears in Collections:2018年度

Files in This Item:

File Description SizeFormat
01乙1425本文の要旨.pdf乙1425本文の要旨2.26 MBAdobe PDFView/Open
02乙1425審査要旨.pdf乙1425審査要旨316 kBAdobe PDFView/Open
03乙1425本文.pdf乙1425本文619.2 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.


Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback